United Wisdom
← Addictions

Society, industries and access to help

How many people take psychotropic medicines for a long time?

The question seems to invite one number. Yet “psychotropic medicines” covers different drugs, while “long term” might mean months, a year, or a decade.

DEP-22-N03EN
Article contents

What this article covers

The question seems to invite one number. Yet “psychotropic medicines” covers different drugs, while “long term” might mean months, a year, or a decade. Reports count prescription items, identified patients, people's accounts of taking a medicine, or consecutive months of dispensing. These are different observations. None, by itself, tells us who benefits, who experiences withdrawal, or who has a substance use disorder (SUD). Three published snapshots show both what we can say and where counting stops.

I. Decide what is being counted

A prescription item is a record of one medicine dispensed, not one person. Someone can receive several items in a year, so the annual total cannot tell us how many years that person has been treated. A count of identified patients is closer to a count of people, but still does not say when each started or why the medicine was prescribed. A person's report of how long they have taken an antidepressant answers another question and depends on recall and the survey's reach. Consecutive dispensing records show a pattern of supply, not proof that every dose was taken.

For that reason, the latest NHS Business Services Authority figures cannot simply be divided into each other to obtain “years of treatment.” The linked methodology describes dispensing in the community, not a person's whole clinical history, and it does not record the indication. Even a “12-month rolling average” is an average of monthly report values, not a statement that a particular patient was treated for twelve months.

II. Three snapshots that cannot be added together

This small comparison table was made for this article. Each row answers a distinct question; the rows do not form one sample or a worldwide percentage.

Place and period Population and measure What it says about duration What it cannot show
United States, 2011–2014 survey Civilian, noninstitutionalized population aged 12+; among people reporting antidepressant use in the previous 30 days 68.0% of that subgroup reported at least two years of use; about one quarter reported at least ten years Not a percentage of all Americans, a 2026 estimate, or an addiction diagnosis
England, March 2018 Adults aged 18+ already receiving a medicine in each of five studied classes, including opioid pain medicines About half of existing recipients in each class had an estimated continuous dispensing history of at least 12 months Not a new starter's chance of continuing for a year, proof of ingestion, or a count of SUD
England, financial year 2025/26 Recorded antidepressant prescription items and estimated identified patients in the dispensing data About 96 million items and 9.1 million patients; no individual duration threshold is reported Neither figure counts long-term users, is restricted here to adults aged 18+, or measures SUD

The US row comes from CDC/NCHS Data Brief 283, published in 2017 using a 2011–2014 survey. If someone used more than one antidepressant, the longest duration was used. This describes people who had taken an antidepressant in the past 30 days; it did not follow a group from their first prescription.

The second row comes from the Public Health England review of 2015–2018 data. It also estimated that about 930,000 antidepressant recipients had continuous dispensing from April 2015 to March 2018. That describes a particular three-year interval, not the exact start of treatment or a diagnosis. The review's five classes are broader than antidepressants; the same person must not be counted twice by casually adding classes. The third row, published on 23 July 2026, shows the current scale of recorded antidepressant dispensing, but contains no measure of how long each person has taken a medicine.

III. Why “patients” does not mean everyone taking a medicine

The English figures use NHS prescriptions dispensed in the community. They may include prescriptions written by a hospital and then filled at a community pharmacy. Medicines dispensed inside hospitals, prisons, and privately are outside this dataset. Patient-record matching can have errors. The publication is revised: the current release corrects an earlier double count in one detailed grouping. So 9.1 million is an estimate of identified patients in a defined data stream, not a list of every resident of England who has ever taken an antidepressant.

Nor does that administrative record show the clinical indication. Antidepressants can be prescribed for more than one condition, including reasons other than depression. A dispensing record does not prove a particular psychiatric diagnosis. Conversely, absence from this stream does not show that someone has no need for care. A count of everyone taking all psychotropic medicines for a long time today would require a common definition of medicine classes and duration, comparable age groups, and other data. These three rows cannot produce it.

IV. A long course, physical adaptation, and SUD are different questions

Prescribed treatment can help. A long course may be an agreed clinical choice, rather than evidence of weak will or “hidden addiction.” There can also be adverse effects and difficulties when treatment changes. The Royal College of Psychiatrists distinguishes antidepressant withdrawal from addiction; physical adaptation does not establish SUD automatically. That distinction does not make difficult withdrawal unreal.

Risks vary by medicine class and circumstance. In January 2026, the MHRA announced stronger dependency and addiction warnings for gabapentinoids, benzodiazepines, and z-drugs while also recognizing benefits of appropriately prescribed treatment. Its warning cannot simply be assigned to every antidepressant or every patient. If you are concerned about benefits, harm, withdrawal, changes in control over use, or a missed dose of a prescribed medicine, ask the prescriber or pharmacist. Do not stop it, change the dose on your own, or attempt withdrawal at home because of a statistics article.

V. Ask a personal question instead of borrowing a population percentage

For your own treatment, a more useful starting point is the specific medicine, the reason it was prescribed, your actual pattern of use, benefits, adverse effects, previous attempts to change it, and the concern you want addressed. You might ask: “What is this medicine intended to do for me now? How will we know whether it helps? What options are there for reviewing treatment, and who would support a change?” An answer depends on your health history, not the average for another country. You need not prove “real addiction” to discuss symptoms or a treatment that is not working well for you.

If you are worried about another adult, the length of that person's course does not entitle you to diagnose them or secretly alter their medicines. With consent, you can offer help arranging an appointment or transport. You can also seek support for your own situation, sharing only what is necessary under applicable local rules. Confidentiality and reporting duties depend on jurisdiction and service; no universal promise of secrecy or custody outcome is possible. Check the language, cost, waiting time, means of contact, and handling of personal data at a service you can actually reach.

VI. Child care and safety need their own decisions

If an adult can no longer provide care safely, a capable adult must actually be available to take responsibility for the child; advice over the phone alone is not supervision. Children should not be asked to monitor pills, judge whether an adult is behaving “normally,” keep a dangerous secret, translate a medical conversation, or manage an adult's treatment. Consent, caregiving duties, and possible involvement of services depend on local circumstances, not a formula in this article.

Threats or violence call for a separate safe route to protection for the person and children. A family argument about medicine must not be a prerequisite to seeking safety. Coercion, lack of housing or money, and barriers of language or access affect what choices are realistically available. A prescription neither explains nor excuses violence; taking a medicine for a long time does not, by itself, make someone dangerous.

VII. An emergency does not wait for a statistical answer

New sudden confusion itself calls for immediate contact with a local emergency medical service for assessment. The NHS guidance on sudden confusion does not require waiting for extreme severity, another sign, a routine appointment, or certainty about the cause. If poisoning is suspected, contact a local emergency medical service immediately, even before symptoms appear, as the NHS poisoning guidance explains. Do not decide at home that it is “just the usual response to a medicine” and delay care to discuss treatment duration. The local route depends on the country; UK phone numbers are not imported here.

Outside an emergency, the next step is smaller: agree with a competent professional on how to assess benefit, risk, and support for this particular person. Someone does not first have to stop treatment, demonstrate moral readiness, explain their use to everyone they know, or attain perfect abstinence to ask for care. Statistics can sharpen the question; the clinical decision remains individual.

VIII. What remains unknown after these numbers

None of these sources gives a single worldwide count of people who take “psychotropic medicines for a long time.” The US and England figures differ in date, population, medicine class, and measurement. One row reports duration among current antidepressant users in a survey; another estimates continuous dispensing among existing recipients of five classes; the latest counts antidepressant items and identified patients without a duration threshold. They cannot be added together, multiplied across the whole population, or turned into a count of SUD.

This limit matters both to someone concerned about overprescribing and to someone helped by medication. We can ask for honest risk measurement, support when treatment changes, and accessible care without calling every long-term user “addicted” or withholding prescribed care for the sake of a neat statistic.

Sources and limits

This is a brief original synthesis of the specified pages, not a translation of their tables, forms, or full texts. Expert clinical, native Thai, local legal, and human review have not yet been performed.

Tags

psychotropic medicines, antidepressants, long-term use, prescription statistics, England, United States, withdrawal, physical adaptation, addiction, child safety, emergency care, access to treatment

About the authors

Andrey Zarinsh — author and founder of United Wisdom. He explores inner transformation, the unity of traditions, intercultural dialogue, and contemporary spiritual discipline. Instagram: @andrey.zarinsh.

Maria Evilkut — co-author of United Wisdom. Alongside her research, she seeks to test these ideas in practice and observe how principles of unity and mutual understanding work in real life between people and cultures. Instagram: @ilkutki.

Content date

15 October 2026. English version.

Choose a reading journey →